Scott Robinson

Dr. Scott Robinson joined Vickers in 2021 and is based in London, UK and Boston, USA. He is the founder of MicroQuin, a biotechnology company developing novel treatments within oncology, anti-infectives and neurodegenerative diseases. Scott is experienced in defining drug development roadmaps with the FDA and EMA for pre-clinical and clinical studies. The winner of numerous ‘Technology in Space’ awards, he continues to work with NASA to design and lead experiments on the international space station. Concurrently, he collaborates with Harvard University, Imperial College London and University of Bristol to develop new treatments for some of the world’s major diseases.

Prior to joining Vickers, Scott worked as a protein biochemist for GlaxoSmithKline. He worked in quantitative Risk Management in Tier 1 Investment Banks including Morgan Stanley, Credit Suisse and Nomura developing Front Office structured credit pricing models and Credit Risk derivatives models.

Scott received his PhD in Cellular and Molecular Biology from Imperial College London and his B.Sc in Microbiology from the University of Bristol, with a Year in Industry in the department of gene expression and protein biochemistry at GlaxoSmithKline.